Država: Irska
Jezik: engleski
Izvor: HPRA (Health Products Regulatory Authority)
Factor viii, human recombinant
Baxalta Innovations GmbH
B02BD; B02BD02
Factor viii, human recombinant
500 IU international unit(s)
Powder and solvent for solution for injection
administered intravenously
Pack size of 1
Product subject to prescription which may not be renewed (A)
antihaemorrhagics: blood coagulation factor VIII
Blood coagulation factors; coagulation factor VIII
Treatment and prophylaxis of bleeding in patients with Haemophilia A (congenital Factor VIII deficiency). This product does not contain von Willebrand factor and is therefore not indicated in von Willebrand’s disease.
Not marketed
1993-10-26
Package leaflet: Information for the user Recombinate 250 IU/10 ml powder and solvent for solution for injection. Recombinate 500 IU/10 ml powder and solvent for solution for injection. Recombinate 1000 IU/10 ml powder and solvent for solution for injection. Octocog alfa (recombinant coagulation factor VIII) Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, or pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects talk to your doctor, or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. What is in this leaflet 1. What Recombinate is and what it is used for 2. What you need to know before you use Recombinate 3. How to use Recombinate 4. Possible side effects 5. How to store Recombinate 6. Contents of the pack and other information 1. What Recombinate is and what it is used for Recombinate belongs to a pharmacotherapeutic group called blood coagulation factor VIII. Recombinate is used in patients with haemophilia A (congenital factor VIII deficiency) for prevention of bleeding treatment of bleeding (e.g. muscle bleeding, oral bleeding, bleeding at the site of surgery). The product does not contain von Willebrand factor and is therefore not to be used in von Willebrand’s disease (a special blood coagulation disorder). 2. What you need to know before you use Recombinate Do not use Recombinate If you are allergic to octocog alfa, to mouse, bovine or hamster proteins or to any of the other ingredients of this medicine (listed in section 6). If you are unsure about this, ask your doctor. Warnings and precautions When allergic reactions occur: There is a rare chance that you may experience an anaphylactic reaction (a severe, sudden allergic reac Pročitajte cijeli dokument
Health Products Regulatory Authority 18 November 2020 CRN00C1DY Page 1 of 11 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Recombinate 500 IU, powder and solvent for solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Octocog alfa 50 IU per ml of reconstituted solution After reconstitution: One vial of 10 ml contains 500 IU octocog alfa Recombinate 500 IU, contains nominally 500 IU octocog alfa, recombinant, coagulation factor VIII per vial. The product contains approximately 50 IU/ml octocog alfa, recombinant coagulation factor VIII when reconstituted with 10 ml of sterile water for injections. The potency is determined using the European Pharmacopoeia chromogenic assay against the FDA Mega Standard calibrated to the WHO Standard. The specific activity of Recombinate is approximately 4000 - 8000 IU/mg protein. Recombinate contains recombinant coagulation factor VIII (INN: octocog alfa). Octocog alfa (recombinant coagulation factor VIII) is a purified protein consisting of 2332 amino acids. It has an amino acid sequence that is comparable to factor VIII, and post-translational modifications that are similar to the plasma derived molecule. Recombinant coagulation factor VIII is a glycoprotein that is expressed by genetically engineered mammalian cells derived from a Chinese Hamster Ovary cell line. Excipients with known effect: sodium For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Powder and solvent for solution for injection. White to off-white friable powder. The solvent (sterilized water for injections) is a clear and colourless liquid. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment and prophylaxis of bleeding in patients with Haemophilia A (congenital Factor VIII deficiency). This product does not contain von Willebrand factor and is therefore not indicated in von Willebrand’s disease. Recombinate is indicated for all age groups from neonates to adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION 4.2.1 POSOLOGY The dosage and duration of Pročitajte cijeli dokument